skip to primary navigationskip to content

Morphogen IX attracts funding to develop treatment for PAH

last modified Jan 21, 2016 03:10 PM

Morphogen-IX has attracted seed funding to develop a new treatment for pulmonary arterial hypertension (PAH). This potential treatment based on 15 years of research by Prof Nick Morrell and others will target the major pathway implicated in genetic studies of patients and, if successful, will provide the first disease-modifying approach to this serious, life-limiting condition.

PAH is caused by a narrowing of the blood vessels that lead from the heart to the lungs. As these arteries narrow, it becomes harder for the heart to pump blood through to the lungs, leading the breathlessness and heart failure.

PAH affects around 6,500 people in the UK, mostly women in their 30s although it can affect people of any age. Current therapies may ease symptoms but there are no medical options that cure the disease. Given the relatively young average age of diagnosis and the high mortality rate associated with PAH, it has a devastating impact on both sufferers and their families.

Morphogen-IX has raised £1.5M in seed funding, led by Index Ventures, along with Cambridge Innovation Capital and Cambridge Enterprise Seed Funds. The company now intends to confirm the best drug candidate to take forward into full development.

To read more, please follow this link to Cambridge Enterprise website.

Cambridge Cardiovascular logo - transparent

Logo design by Dr Ana-Mishel Spiroski and Dr Sarah Morgan.


We connect cardiovascular researchers in Cambridge.

Please follow us on Twitter for local news about research, events, funding calls, and open positions.

For inquiries about our research or the website, please contact Dr Tammy Dougan